Baaritaanka hidda-sidaha kansarka
Tijaabada hidda-wadaha kansarku waxay hagtaa daawaynta la beegsanayo inay tahay tignoolajiyada udub-dhexaadka u ah daawaynta saxda ah ee kansarka. Bukaan kasta oo kansar ah waa inuu naftiisa u sameeyaa baaritaanka hidda-wadaha kansarka, isaga oo raadinaya dawooyin la beegsanayo oo waxtar leh iyo tijaabooyin caafimaad oo daaweyn ah. Shabakada Caalamiga ah ee Oncologist, iyada oo lala kaashanayo wakaaladda baadhista hidaha ee Maraykanka iyo hay'adda baadhista hidaha ee heer-sare ee gudaha, waxay siisaa bukaannada baaritaanka hidde-sidaha kansarka saxda ah iyo adeegyo la-talin khubaro ah si ay uga caawiyaan bukaannada inay dejiyaan qorshaha daaweynta ugu saxsan.
FDA waxay dhawaan ansixisay Iressa inay tahay daawayn hal-wakiil ah oo loogu talagalay kansarka sambabada unugyada aan-yaraha ahayn ee metastatic (NSCLC) oo ku habboon isbeddellada soo-dhowaynta korriinka koritaanka epidermal (EGFR) ee ay xaqiijisay xirmada ogaanshaha saaxiibka ee FDA-ansixisay.
Iressa waa dawadii ugu horeysay ee loo bartilmaansado molecularly ee loogu talagalay daaweynta kansarka sanbabada ee Shiinaha. Waxaa si rasmi ah looga bilaabay Shiinaha iyada oo oggolaansho laga helay Maamulka Cuntada iyo Dawooyinka ee Gobolka 2005, iyada oo fureysa xilli cusub oo daaweyn loogu talagalay bukaannada qaba kansarka sambabada unugyada unugyada yaryar. Iressa waxay u keentaa bukaanada kansarka sanbabada ee Shiinaha ikhtiyaaro daawaynta la hagaajiyay si ay u wanaajiyaan tayada noloshooda waxayna u janjeeraan inay sii dheereeyaan badbaadadooda. Sanadguuradii 6aad ee liiska Iressa, Iressa waxaa sidoo kale loo ansixiyay inay noqoto daawaynta safka koowaad ee kansarka sambabada unugyada yaryar.
Kansarka sanbabada waa kansarka nambarka koowaad ee heerarka dhimashada burooyinka la xiriira ee Shiinaha. Kansarka sambabada unugyada aan yarayn (NSCLC) ayaa qiyaastii ah 85% dhammaan kiisaska kansarka sanbabada.
Waqtigan xaadirka ah, daawaynta kansarka sanbabada ayaa weli ah qalliin, daawaynta shucaaca, iyo daawaynta daroogada. Daawaynta maandooriyaha ee kansarka sambabada waxa ka mid ah daawaynta kimoterabiga iyo daawaynta molecularly bartilmaameedka ah ee daawaynta (caado u ah EGFR-TKIs).
Daawaynta kansarka sanbabada, gaar ahaan kansarka sanbabada unug yar, waxay u dooddaa qaab daawaynta shakhsi ahaaneed. Waxay ku salaysan tahay heerka muujinta hidda-wadaha darawalka ee bukaannada kansarka sambabada, taas oo ah, daawaynta shakhsi ahaaneed ee ku salaysan in bukaannada kansarka sanbabada ay leeyihiin hidde-sideyaasha darawalka. Waxaa ka mid ah, soo-dhoweynta korriinka koritaanka epidermal (EGFR) waxaa iska leh tyrosine kinase reseptor, iyo dariiqa gudbinta calaamaduhu waxay nidaamisaa koritaanka unugyada, faafinta iyo kala duwanaanta. Kansarka, waxaa la ogaaday in isbeddello kala duwan ay inta badan ku dhacaan gobolka EGFR tyrosine kinase. Isbeddelladani waxay si dhow ula xiriiraan waxtarka tyrosine kinase inhibitors. Isbedelka EGFR waa darawalka kansarka oo muhiim ah. Isbeddellada EGFR waa saadaalin xooggan oo ah in bukaannada kansarku ay u nugul yihiin TKI iyo in kale. Sidaa darteed, ogaanshaha isbeddellada hidda-wadaha EGFR waxay ku siin kartaa saldhig daawaynta la beegsaday. Heerka isbeddelka EGFR ee bukaannada kansarka sanbabada ee Shiinaha waa 30% -40%.
Goobaha beddelka hidda-wadaha EGFR ayaa go'aamiya in bukaannada kansarka sanbabada unugyada aan yareyn ay isticmaali karaan Iressa, Tarceva iyo daroogooyinka kale ee la beegsaday. Isbeddellada Iressa / Trokai ee exons 18, 19, 20, iyo 21, gaar ahaan tirtiridda exon 19 ama beddelka exon 21, waxay leeyihiin saamayn weyn. Waxaa lagu talinayaa in bukaanada qaba kansarka sanbabada unug yar ay maraan baaritaanka hidda-socodka ka hor intaysan isticmaalin daawooyinka la beegsanayo sida Iressa / Troca.
